What is FRAT (Folate Receptor Autoantibody Test)?
FRAT is a blood test that measures autoantibodies against folate receptor alpha (FRα), which can block folate transport into the brain and cause cerebral folate deficiency despite normal serum folate levels.
Clinical Significance
The Folate Receptor Autoantibody Test detects antibodies (both IgG and IgM) that bind to or block folate receptor alpha, the primary transporter responsible for delivering folate across the blood-brain barrier through the choroid plexus 1, 2. When these autoantibodies are present, they can:
- Impair folate transport into the CNS, leading to cerebral folate deficiency (CFD) even when systemic folate levels are normal 3, 4
- Interfere with folate receptor function at the blood-brain barrier and in renal tubules (where FRα also mediates folate reabsorption) 1
- Disrupt one-carbon metabolism essential for nucleic acid synthesis, neurotransmitter production, and myelin integrity 5, 4
Testing Methodology
FRAA testing is performed using enzyme-linked immunosorbent assay (ELISA) with purified folate receptor alpha as the antigen 6. The test typically measures:
- Binding antibodies: Antibodies that attach to FRα
- Blocking antibodies: Antibodies that specifically prevent folate from binding to FRα
- Soluble folate receptor (sFR): Circulating FRα fragments, which when elevated may indicate receptor shedding or damage 2
Clinical Applications
Neurodevelopmental Disorders
FRAA has been associated with autism spectrum disorder (ASD), pediatric acute-onset neuropsychiatric syndrome (PANS), and other neurodevelopmental conditions where cerebral folate deficiency may contribute to symptoms 2, 4.
Neuropsychiatric Conditions
- Multiple sclerosis: 85% of RRMS patients tested positive for FRAA versus 47% of controls, with significantly higher antibody titers 5
- Major depressive disorder: High FRAA titers correlate with folate deficiency and reduced response to SSRI/SNRI treatment in adolescents 3
Pregnancy and Neural Tube Defects
First-trimester FRAA testing may identify women at risk for impaired placental folate transport, with provisional clinical thresholds at P95 ≈ 120 ng/mL and P99 ≈ 150 ng/mL 1. Women who previously had babies with neural tube defects show elevated FRAA levels 6.
Vector-Borne Diseases
A striking 62% prevalence of FRAA was found in patients with Borrelia, Bartonella, and Babesia infections, with soluble folate receptor strongly associated with Borrelia species 2.
Clinical Interpretation
Positive FRAA results indicate increased risk of cerebral folate deficiency and may warrant:
- Folinic acid (5-formyltetrahydrofolate) supplementation, which can bypass the blocked receptor
- Investigation for underlying autoimmune or infectious triggers
- Monitoring of neurological and psychiatric symptoms
Key distinction: Unlike standard folic acid supplementation (which requires FRα for CNS entry), folinic acid can cross the blood-brain barrier through alternative pathways when FRα is blocked by autoantibodies 4.
Important Caveats
- FRAA can cause cerebral folate deficiency even when serum folate levels are normal, making standard folate testing insufficient for diagnosis 3
- The test is most informative when performed before 15 weeks of gestation in pregnant women, as this precedes the onset of accelerated transplacental IgG transfer 1
- Reference ranges and clinical thresholds are still being established and may vary by laboratory and clinical context 1